Keros Corp (KROS) Enterprise Value to EBITDA Ratio

Public company logo of kerostx.com (KROS)

The low predictability of Keros Therapeutics (KROS) cash flows is driven by its laboratory research stage, which is confirmed by the EV/EBITDA value including total debt shown on this GURU.Markets chart, where 0.00 captures the current state of the parameter. Profit prospects are based on therapies for anemia and bone pathologies, while investment inflows rely on clinical data under full FDA oversight.

Keros Therapeutics Inc - KROS Company Value to EBITDA (period 11/23/2025 - 11/16/2026)

Comprehensive metric breakdowns and analytics for Keros Therapeutics Inc (KROS)

- current price and projected stock value:
Fundamental valuation:Keros Therapeutics KROS
Manufactured products of Keros Therapeutics, Inc.

Assessing the investment reliability of equity assets begins with analyzing the ratio of total enterprise value to operating profit before depreciation and interest. For Keros Therapeutics (KROS), which is developing a TGF-beta protein modulation platform, the company's EV/EBITDA value on this chart reflects the efficiency of capitalizing innovations in rare disease therapy, allowing for a determination of the asset's overvaluation relative to its actual cash flow.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|Enterprise Value to EBITDA Ratio BGM|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Biosciences, Inc.)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma Holdings)|ARCT (Arcturus Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Corp) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (abeonatherapeutics.com)|MREO: EV/EBITDA Multiple|Protalix BioTherapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pliantrx.com|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aileronrx.com (RNTX)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI